Sangamo Therapeutics (SGMO) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results
May 5, 2022 4:01 PM EDTConference Call and Webcast Scheduled for 4:30 p.m. Eastern Time
BRISBANE, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and first quarter 2022 financial results.
This quarter, we have continued to progress multiple programs through clinical development and demonstrated, once again, Sangamos track record of advancing groundbreaking therapies in genomic medicine, said Sandy Macrae, Chief Executive Officer of Sangamo. We dosed a total of five patients across three programs, including the first patient in our study for the... More
